Related Experiment Video
Updated: Sep 27, 2026

Rose Bengal-Mediated Photodynamic Therapy to Inhibit Candida albicans
Published on: March 24, 2022
Topical rose bengal: pre-clinical evaluation of pharmacokinetics and safety
Eric Wachter1, Craig Dees, Jay Harkins
1Provectus Pharmaceuticals, Inc., Knoxville, Tennessee 37931, USA. wachter@provectuscorp.com
Background And Objectives:
Rose bengal (RB) is a potent photosensitizer that has largely been overlooked as a potential photodynamic therapy (PDT) agent. In this study, the feasibility of topical delivery of RB to the epidermis has been evaluated.
Study Design/Materials And Methods:
Topical formulations of RB were assessed on murine and rabbit skin for pharmacokinetic properties, cutaneous toxicity, and photosensitization.
Results:
Hydrophilic formulations (
Conclusions:
These results indicate that RB is safe for PDT treatment of skin disorders, exhibiting negligible effects in normal skin.
More Related Videos
Related Concept Videos
Preclinical Development: Overview
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Modified-Release Drug Delivery Systems: Bioavailability
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Bioavailability Study Design: Single Versus Multiple Dose Studies

